Stock Plummets Despite Strong Earnings: Genetic Testing Shares Drop Over 10% in a Day

On the Nasdaq, Natera Inc. (NTRA) shares plunged 11.52% from the prior close to $194.50, erasing roughly $2.85 billion in market capitalization—about ₩4 trillion—in a single session. Trading volume exceeded 3.04 million shares, well above average, as investors both took profits following the earnings release and reacted to valuation pressures. (investing.com)

Natera yesterday reported first-quarter revenue of $696.6 million—approximately ₩1 trillion—a 39% increase year-over-year. The company raised its full-year 2026 revenue guidance to $2.74–2.82 billion, or about ₩3.8–3.9 trillion. However, a net loss of $85.1 million in the quarter underscored its continued unprofitability, heightening market scrutiny on the balance between growth and profitability. (businesswire.com)

Headquartered in Austin, Texas, Natera is a clinical genetic testing firm that leverages cell-free DNA technology to deliver noninvasive diagnostic services in maternal health, oncology and organ transplantation. Since its 2004 founding, the company has emerged as a leader in precision medicine with its proprietary molecular biology and bioinformatics platforms, fueling a strong rally that has positioned it at the forefront of the U.S. genomics diagnostics sector. (natera.com)